Europe Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemical Industry, Food Industry, and Others) – Opportunity Analysis and Industry Forecast, 2023-2030

Europe Early Toxicity Testing Market

Industry:  Life Sciences & Healthcare | Publish Date: Aug 2023 | No of Pages:  157 | No. Tables:  132 | No. Figures:  81

Market Definition

Europe Early Toxicity Testing Market was valued at USD 1.07 billion in 2022, and is predicted to reach USD 2.19 billion by 2030, with a CAGR of 8.04% from 2023 to 2030.

Early toxicity testing is a fundamental procedure aimed at assessing the potential toxicity or adverse effects of drugs, chemicals, or various substances during their preliminary developmental stages. Typically conducted in vitro or through animal models, this evaluation occurs prior to any human testing.

The overarching objective of early toxicity testing is to swiftly uncover any safety-related apprehensions linked to a substance, thus facilitating informed decisions about its feasibility for continued development and subsequent testing. 

By undertaking early toxicity testing, the risks of adverse effects on both human subjects and animals during clinical trials are mitigated, simultaneously curtailing expenses and time invested in the overall drug development trajectory.

This intricate process encompasses a gamut of examinations and assays, encompassing cell viability assessments, genotoxicity evaluations, and pharmacokinetic investigations. 

The specific modalities employed are contingent on the intrinsic nature of the substance under scrutiny and its intended application. Recognized as an indispensable phase within the drug development journey, early toxicity testing profoundly bolsters the assurance of safety and efficacy for novel drugs and other substances, prior to their regulatory endorsement for human utilization.

Surge in Chronic Diseases in Developed European Nations Fuels ETT Market Growth

Europe consists of developed nations such as the UK, Germany, and Denmark. Growth in prevalence of chronic diseases in Europe that may require long-term treatment with medications, which can have toxic effects on body propels growth of the ETT market.

The surge in chronic diseases represents a pressing health concern that has far-reaching implications. Conditions such as cardiovascular diseases, diabetes, cancer, and neurological disorders are increasingly prevalent within the European population. As these chronic diseases become more widespread, the necessity for effective and safe treatment regimens has gained paramount importance.

For instance, 35% or more than one-third of the population in the region reported a long-standing chronic health problem in 2021.

 

Escalating Investments in Research and Development Catalyze Market Expansion in Europe

The increase in investments in research and development by pharmaceutical companies and governments in this region further drives the market growth. As a critical aspect of drug development, early toxicity testing is experiencing significant growth in Europe, and it is expected to continue as pharmaceutical companies aim to meet rise in demand for innovative medicines.

 

Regulatory Constraints and their Impact on Early Toxicity Testing Market Growth in Europe

However, stringent regulations set by regulatory bodies such as the US FDA and the EMA require extensive and rigorous testing for drug development and safety, which can be time-consuming and expensive and restrain growth of the market. The complexity and cost of complying with these regulations can pose a significant challenge for small and medium-sized companies that may not have the resources to carry out extensive testing.

As a result, some companies may choose to delay or abandon drug development projects, which can limit demand for early toxicity testing services. 

Moreover, stringent regulations can also result in a lengthy approval process for new drugs, further delaying the time it takes for drugs to reach the market. This, in turn, is expected to hamper growth of the market.

Technological Advancements in the field of Early Toxicity Testing Market in Europe

Introduction of new technologies such as in-vitro modelling using 3D cell culture is expected to provide new lucrative opportunities for the early toxicity testing market during the forecast period. Use of 3D cell cultures can better mimic complexity of tissues and organs, providing more accurate and reliable results for toxicity testing.

Traditional 2D cell culture models are limited in their ability to mimic complexity of human tissues and organs, often leading to inaccurate and unreliable results in toxicity testing. 

However, use of 3D cell culture models can better mimic structural and functional complexity of tissues and organs, providing more accurate and reliable results for toxicity testing.

3D cell cultures allow growth and interaction of multiple cell types, creating a microenvironment that more closely resembles human tissues and organs. This can better predict toxic effects of drugs and chemicals in the human body, reducing the risk of adverse effects in clinical trials. Hence, such factors propel the market growth.

 

Competitive Landscape  

The Europe early toxicity testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG., and Thermo Fisher Scientific Inc.

KEY BENEFITS

  • The Europe early toxicity testing market report provides a quantitative analysis of the current market and estimations through 2023-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the market trend including the current and future trends for depicting the prevalent investment pockets in the industry.

  • The information related to key drivers, restraints, and opportunities and their impact on the market is provided in the report.

  • The competitive analysis of the key players along with their market share in the Europe early toxicity testing market.

  • The SWOT analysis and Porter’s Five Forces model are elaborated in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

EUROPE EARLY TOXICITY TESTING MARKET KEY SEGMENTS

By Technique

  • In Vivo

  • In Vitro

    • Cell Culture    

    • PCR    

    • ELISA    

    • Western Blotting    

    • Protein Binding Assays    

  • In Silico    

By Toxicity Endpoint

  • Genotoxicity    

  • Dermal Toxicity 

  • Skin Toxicity 

  • Ocular Toxicity    

  • Phototoxicity    

  • Others    

By End User

  • Pharmaceutical Industry    

  • Cosmetic Industry    

  • Chemical Industry    

  • Food Industry     

  • Others    

By Geography

  • Europe

    • The UK

    • Germany

    • France

    • Spain

    • Italy

    • Netherlands

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Russia

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2022

USD 1.07 Billion

Revenue Forecast in 2030

USD 2.19 Billion

Growth Rate

CAGR of 8.04% from 2023 to 2030

Analysis Period

2022–2030

Base Year Considered

2022

Forecast Period

2023–2030

Market Size Estimation

Billion (USD)

Growth Factors

The surge in chronic diseases.

 

Escalating investments in research and development.

Countries Covered

11

Companies Profiled

15

Market Share

Available for 15 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2       EUROPE EARLY TOXICITY TESTING MARKET BY TECHNIQUE

           2.1      OVERVIEW

           2.2      IN VIVO

                         2.2.1      IN VIVO MARKET, BY COUNTRY

           2.3      IN VITRO

                         2.3.1      IN VITRO MARKET, BY TECHNIQUE

                                          2.3.1.1      CELL CULTURE MARKET, BY COUNTRY

                                          2.3.1.2      PCR MARKET, BY COUNTRY

                                          2.3.1.3      ELISA MARKET, BY COUNTRY

                                          2.3.1.4      WESTERN BLOTTING MARKET, BY COUNTRY

                                          2.3.1.5      PROTEIN BINDING ASSAYS MARKET, BY COUNTRY

                         2.3.2      IN VITRO MARKET, BY COUNTRY

           2.4      IN SILICO

                         2.4.1      IN SILICO MARKET, BY COUNTRY

3       EUROPE EARLY TOXICITY TESTING MARKET BY TOXICITY ENDPOINT

           3.1      OVERVIEW

           3.2      GENOTOXICITY

                         3.2.1      GENOTOXICITY MARKET, BY COUNTRY

           3.3      DERMAL TOXICITY

                         3.3.1      DERMAL TOXICITY MARKET, BY COUNTRY

           3.4      SKIN TOXICITY

                         3.4.1      SKIN TOXICITY MARKET, BY COUNTRY

           3.5      OCULAR TOXICITY

                         3.5.1      OCULAR TOXICITY MARKET, BY COUNTRY

           3.6      PHOTOTOXICITY

                         3.6.1      PHOTOTOXICITY MARKET, BY COUNTRY

           3.7      OTHERS

                         3.7.1      OTHERS MARKET, BY COUNTRY

4       EUROPE EARLY TOXICITY TESTING MARKET BY END USER

           4.1      OVERVIEW

           4.2      PHARMACEUTICAL INDUSTRY

                         4.2.1      PHARMACEUTICAL INDUSTRY MARKET, BY COUNTRY

           4.3      COSMETIC INDUSTRY

                         4.3.1      COSMETIC INDUSTRY MARKET, BY COUNTRY

           4.4      CHEMICAL INDUSTRY

                         4.4.1      CHEMICAL INDUSTRY MARKET, BY COUNTRY

           4.5      FOOD INDUSTRY

                         4.5.1      FOOD INDUSTRY MARKET, BY COUNTRY

           4.6      OTHERS

                         4.6.1      OTHERS MARKET, BY COUNTRY

5      EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY

           5.1     OVERVIEW

           5.2     GERMANY

                         5.2.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.2.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.2.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.3     FRANCE

                         5.3.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.3.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.3.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.4     ITALY

                         5.4.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.4.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.4.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.5     SPAIN

                         5.5.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.5.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.5.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.6     UNITED KINGDOM

                         5.6.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.6.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.6.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.7     RUSSIA

                         5.7.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.7.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.7.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.8     SWEDEN

                         5.8.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.8.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.8.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.9     NORWAY

                         5.9.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.9.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.9.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.10     DENMARK

                         5.10.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.10.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.10.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.11     NETHERLANDS

                         5.11.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.11.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.11.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.12     FINLAND

                         5.12.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.12.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.12.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

           5.13     REST OF EUROPE

                         5.13.1     EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.13.2     EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.13.3     EUROPE EARLY TOXICITY TESTING MARKET, BY END USER

6      COMPANY PROFILES

           6.1   INOTIV INC.

                         6.1.1   COMPANY OVERVIEW

                         6.1.2   COMPANY SNAPSHOT

                         6.1.3   OPERATING BUSINESS SEGMENTS

                         6.1.4   PRODUCT PORTFOLIO

                         6.1.5   BUSINESS PERFORMANCE

                         6.1.6   BUSINESS SEGMENTS

                         6.1.7   GEOGRAPHIC SEGMENTS

                         6.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.1.9   PRIMARY MARKET COMPETITORS

           6.2   BIO-RAD LABORATORIES INC.

                         6.2.1   COMPANY OVERVIEW

                         6.2.2   COMPANY SNAPSHOT

                         6.2.3   OPERATING BUSINESS SEGMENTS

                         6.2.4   PRODUCT PORTFOLIO

                         6.2.5   BUSINESS PERFORMANCE

                         6.2.6   BUSINESS SEGMENTS

                         6.2.7   GEOGRAPHIC SEGMENTS

                         6.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.2.9   PRIMARY MARKET COMPETITORS

           6.3   EVOTEC A.G.

                         6.3.1   COMPANY OVERVIEW

                         6.3.2   COMPANY SNAPSHOT

                         6.3.3   OPERATING BUSINESS SEGMENTS

                         6.3.4   PRODUCT PORTFOLIO

                         6.3.5   BUSINESS PERFORMANCE

                         6.3.6   BUSINESS SEGMENTS

                         6.3.7   GEOGRAPHIC SEGMENTS

                         6.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.3.9   PRIMARY MARKET COMPETITORS

           6.4   AGILENT TECHNOLOGIES INC.

                         6.4.1   COMPANY OVERVIEW

                         6.4.2   COMPANY SNAPSHOT

                         6.4.3   OPERATING BUSINESS SEGMENTS

                         6.4.4   PRODUCT PORTFOLIO

                         6.4.5   BUSINESS PERFORMANCE

                         6.4.6   BUSINESS SEGMENTS

                         6.4.7   GEOGRAPHIC SEGMENTS

                         6.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.4.9   PRIMARY MARKET COMPETITORS

           6.5   WUXI APPTEC

                         6.5.1   COMPANY OVERVIEW

                         6.5.2   COMPANY SNAPSHOT

                         6.5.3   OPERATING BUSINESS SEGMENTS

                         6.5.4   PRODUCT PORTFOLIO

                         6.5.5   BUSINESS PERFORMANCE

                         6.5.6   BUSINESS SEGMENTS

                         6.5.7   GEOGRAPHIC SEGMENTS

                         6.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.5.9   PRIMARY MARKET COMPETITORS

           6.6   BRUKER

                         6.6.1   COMPANY OVERVIEW

                         6.6.2   COMPANY SNAPSHOT

                         6.6.3   OPERATING BUSINESS SEGMENTS

                         6.6.4   PRODUCT PORTFOLIO

                         6.6.5   BUSINESS PERFORMANCE

                         6.6.6   BUSINESS SEGMENTS

                         6.6.7   GEOGRAPHIC SEGMENTS

                         6.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.6.9   PRIMARY MARKET COMPETITORS

           6.7   PERKINELMER INC.

                         6.7.1   COMPANY OVERVIEW

                         6.7.2   COMPANY SNAPSHOT

                         6.7.3   OPERATING BUSINESS SEGMENTS

                         6.7.4   PRODUCT PORTFOLIO

                         6.7.5   BUSINESS PERFORMANCE

                         6.7.6   BUSINESS SEGMENTS

                         6.7.7   GEOGRAPHIC SEGMENTS

                         6.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.7.9   PRIMARY MARKET COMPETITORS

           6.8   ENZO BIOCHEM INC.

                         6.8.1   COMPANY OVERVIEW

                         6.8.2   COMPANY SNAPSHOT

                         6.8.3   OPERATING BUSINESS SEGMENTS

                         6.8.4   PRODUCT PORTFOLIO

                         6.8.5   BUSINESS PERFORMANCE

                         6.8.6   BUSINESS SEGMENTS

                         6.8.7   GEOGRAPHIC SEGMENTS

                         6.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.8.9   PRIMARY MARKET COMPETITORS

           6.9   DANAHER CORPORATION

                         6.9.1   COMPANY OVERVIEW

                         6.9.2   COMPANY SNAPSHOT

                         6.9.3   OPERATING BUSINESS SEGMENTS

                         6.9.4   PRODUCT PORTFOLIO

                         6.9.5   BUSINESS PERFORMANCE

                         6.9.6   BUSINESS SEGMENTS

                         6.9.7   GEOGRAPHIC SEGMENTS

                         6.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.9.9   PRIMARY MARKET COMPETITORS

           6.10   EUROFINS SCIENTIFIC SE

                         6.10.1   COMPANY OVERVIEW

                         6.10.2   COMPANY SNAPSHOT

                         6.10.3   OPERATING BUSINESS SEGMENTS

                         6.10.4   PRODUCT PORTFOLIO

                         6.10.5   BUSINESS PERFORMANCE

                         6.10.6   BUSINESS SEGMENTS

                         6.10.7   GEOGRAPHIC SEGMENTS

                         6.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.10.9   PRIMARY MARKET COMPETITORS

           6.11   CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

                         6.11.1   COMPANY OVERVIEW

                         6.11.2   COMPANY SNAPSHOT

                         6.11.3   OPERATING BUSINESS SEGMENTS

                         6.11.4   PRODUCT PORTFOLIO

                         6.11.5   BUSINESS PERFORMANCE

                         6.11.6   BUSINESS SEGMENTS

                         6.11.7   GEOGRAPHIC SEGMENTS

                         6.11.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.11.9   PRIMARY MARKET COMPETITORS

           6.12   LABCORP DRUG DEVELOPMENT.

                         6.12.1   COMPANY OVERVIEW

                         6.12.2   COMPANY SNAPSHOT

                         6.12.3   OPERATING BUSINESS SEGMENTS

                         6.12.4   PRODUCT PORTFOLIO

                         6.12.5   BUSINESS PERFORMANCE

                         6.12.6   BUSINESS SEGMENTS

                         6.12.7   GEOGRAPHIC SEGMENTS

                         6.12.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.12.9   PRIMARY MARKET COMPETITORS

           6.13   PROMEGA CORPORATION

                         6.13.1   COMPANY OVERVIEW

                         6.13.2   COMPANY SNAPSHOT

                         6.13.3   OPERATING BUSINESS SEGMENTS

                         6.13.4   PRODUCT PORTFOLIO

                         6.13.5   BUSINESS PERFORMANCE

                         6.13.6   BUSINESS SEGMENTS

                         6.13.7   GEOGRAPHIC SEGMENTS

                         6.13.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.13.9   PRIMARY MARKET COMPETITORS

           6.14   INSPHERO AG

                         6.14.1   COMPANY OVERVIEW

                         6.14.2   COMPANY SNAPSHOT

                         6.14.3   OPERATING BUSINESS SEGMENTS

                         6.14.4   PRODUCT PORTFOLIO

                         6.14.5   BUSINESS PERFORMANCE

                         6.14.6   BUSINESS SEGMENTS

                         6.14.7   GEOGRAPHIC SEGMENTS

                         6.14.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.14.9   PRIMARY MARKET COMPETITORS

           6.15   THERMO FISHER SCIENTIFIC INC.

                         6.15.1   COMPANY OVERVIEW

                         6.15.2   COMPANY SNAPSHOT

                         6.15.3   OPERATING BUSINESS SEGMENTS

                         6.15.4   PRODUCT PORTFOLIO

                         6.15.5   BUSINESS PERFORMANCE

                         6.15.6   BUSINESS SEGMENTS

                         6.15.7   GEOGRAPHIC SEGMENTS

                         6.15.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.15.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 2. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 3. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 4. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 5. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

TABLE 6. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 7. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 8. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 9. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 10. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 11. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 12. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 13. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 14. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 15. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 16. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 17. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 18. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 19. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 20. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 21. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 22. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 23. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 24. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 25. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 26. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 27. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 28. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 29. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 30. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 31. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 32. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 33. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 34. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 35. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 36. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 37. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 38. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 39. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 40. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 41. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 42. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 43. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 44. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 45. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 46. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 47. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 48. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 49. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 50. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 51. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 52. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 53. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 54. INOTIV INC.: COMPANY SNAPSHOT

TABLE 55. INOTIV INC: OPERATING SEGMENTS

TABLE 56. INOTIV INC.: PR0DUCT PORTFOLIO

TABLE 57. INOTIV INC.: BUSINESS SEGMENT

TABLE 58. INOTIV INC.: GEOGRAPHIC SEGMENT

TABLE 59. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 60. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT

TABLE 61. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS

TABLE 62. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 63. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT

TABLE 64. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT

TABLE 65. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 66. EVOTEC A.G.: COMPANY SNAPSHOT

TABLE 67. EVOTEC A.G.: OPERATING SEGMENTS

TABLE 68. EVOTEC A.G.: PRODUCT PORTFOLIO

TABLE 69. EVOTEC A.G.: BUSINESS SEGMENT

TABLE 70. EVOTEC A.G.: GEOGRAPHIC SEGMENT

TABLE 71. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 72. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT

TABLE 73. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS

TABLE 74. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO

TABLE 75. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT

TABLE 76. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT

TABLE 77. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 78. WUXI APPTEC.: COMPANY SNAPSHOT

TABLE 79. WUXI APPTEC: OPERATING SEGMENTS

TABLE 80. WUXI APPTEC.: PR0DUCT PORTFOLIO

TABLE 81. WUXI APPTEC.: BUSINESS SEGMENT

TABLE 82. WUXI APPTEC.: GEOGRAPHIC SEGMENT

TABLE 83. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 84. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 85. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 86. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 87. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT

TABLE 88. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT

TABLE 89. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 90. BRUKER: COMPANY SNAPSHOT

TABLE 91. BRUKER: OPERATING SEGMENTS

TABLE 92. BRUKER: PRODUCT PORTFOLIO

TABLE 93. BRUKER: BUSINESS SEGMENT

TABLE 94. BRUKER: GEOGRAPHIC SEGMENT

TABLE 95. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 96. PERKINELMER INC.: COMPANY SNAPSHOT

TABLE 97. PERKINELMER INC.: OPERATING SEGMENTS

TABLE 98. PERKINELMER INC.: PRODUCT PORTFOLIO

TABLE 99. PERKINELMER INC.: BUSINESS SEGMENT

TABLE 100. PERKINELMER INC.: GEOGRAPHIC SEGMENT

TABLE 101. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 102. ENZO BIOCHEM INC.: COMPANY SNAPSHOT

TABLE 103. ENZO BIOCHEM INC.: OPERATING SEGMENTS

TABLE 104. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO

TABLE 105. ENZO BIOCHEM INC.: BUSINESS SEGMENT

TABLE 106. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT

TABLE 107. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 108. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 109. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 110. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 111. DANAHER CORPORATION: BUSINESS SEGMENT

TABLE 112. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 113. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT

TABLE 114. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO

TABLE 115. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT

TABLE 116. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 117. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT

TABLE 118. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS

TABLE 119. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO

TABLE 120. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT

TABLE 121. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT

TABLE 122. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 123. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT

TABLE 124. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS

TABLE 125. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO

TABLE 126. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT

TABLE 127. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT

TABLE 128. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 129. PROMEGA CORPORATION: COMPANY SNAPSHOT

TABLE 130. PROMEGA CORPORATION: PRODUCT PORTFOLIO

TABLE 131. INSPHERO AG: COMPANY SNAPSHOT

TABLE 132. INSPHERO AG: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 2. EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 3. EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 4. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 5. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 6. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 7. UK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 8. UK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 9. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 10. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 11. GERMANY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 12. GERMANY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 13. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 14. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 15. FRANCE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 16. FRANCE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 17. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 18. ITALY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 19. ITALY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 20. ITALY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 21. ITALY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 22. SPAIN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 23. SPAIN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 24. SPAIN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 25. SPAIN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 26. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 27. NETHERLANDS IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 28. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 29. NETHERLANDS EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 30. DENMARK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 31. DENMARK IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 32. DENMARK EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 33. DENMARK EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 34. FINLAND EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 35. FINLAND IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 36. FINLAND EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 37. FINLAND EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 38. NORWAY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 39. NORWAY IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 40. NORWAY EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 41. NORWAY EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 42. SWEDEN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 43. SWEDEN IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 44. SWEDEN EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 45. SWEDEN EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 46. RUSSIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 47. RUSSIA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 48. RUSSIA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 49. RUSSIA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 50. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 51. REST OF EUROPE IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 52. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 53. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 54. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 55. INOTIV INC: PRIMARY MARKET COMPETITORS

FIGURE 56. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 57. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS

FIGURE 58. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)

FIGURE 59. EVOTEC A.G.: PRIMARY MARKET COMPETITORS

FIGURE 60. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)

FIGURE 61. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS

FIGURE 62. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 63. WUXI APPTEC: PRIMARY MARKET COMPETITORS

FIGURE 64. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)

FIGURE 65. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS

FIGURE 66. BRUKER: NET SALES, 2019–2021 ($MILLION)

FIGURE 67. BRUKER: PRIMARY MARKET COMPETITORS

FIGURE 68. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 69. PERKINELMER INC.: PRIMARY MARKET COMPETITORS

FIGURE 70. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 71. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS

FIGURE 72. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)

FIGURE 73. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 74. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 75. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS

FIGURE 76. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 77. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS

FIGURE 78. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 79. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS

FIGURE 80. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 81. INSPHERO AG: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Inotiv Inc.

  • Bio-Rad Laboratories Inc

  • Evotec A.G. 

  • Agilent Technologies Inc

  • Wuxi Apptec

  • Bruker

  • Perkinelmer Inc.

  • Enzo Biochem Inc.

  • Danaher Corporation

  • Eurofins Scientific SE

  • Charles River Laboratories International, Inc.

  • Labcorp Drug Development.

  • Promega Corporation

  • Insphero AG

  • Thermo Fisher Scientific Inc.


Frequently Asked Questions
What will be the worth of Europe early toxicity testing market by the end of 2030?

According to the report published by the Next Move Consulting, the Europe early toxicity testing market business is expected to hit at $2.19 billion (USD) by 2030.

What are the leading companies in the Europe early toxicity testing market?

The Europe early toxicity testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG, and Thermo Fisher Scientific Inc.

What are the market segmentations and scope of the study for the Europe early toxicity testing industry?

The Europe early toxicity testing market share is segmented on the basis of technique, toxicity endpoint, and end user.

What factors are propelling the growth of the Europe early toxicity testing market?

The factors propelling the growth of the Europe early toxicity testing market are surge in chronic diseases, escalating investments in research and development, and technological advancements.

What factors are hindering the growth of the Europe early toxicity testing market?

The factors hindering the growth of the Europe early toxicity testing market are high initial costs and stringent regulatory compliance.